肿瘤细胞治疗研究
DISEASE HUB
FOR TREATMENT
现在就能报名的(招募中)排在最前,共 2 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov、CDE 与 ChiCTR 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
The search for safe and effective CAR-T targets in AML.
Bicistronic CAR T-cells Against CD70 & Active Integrin β2 Overcome Antigen Heterogeneity and Preserve Safety in Acute Myeloid Leukemia.
IL-21/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。